US EditionTriplet Therapy Significantly Improves Survival in BRAF V600E-Mutated Metastatic Colorectal Cancer
7 Articles
7 Articles
Triplet therapy significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer
First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the Phase III BREAKWATER trial led by researchers from The University of Texas MD Anderson Cancer Center.
"BREAKWATER's results are the first promising survival results ever reported for metastatic colorectal cancer with BRAF mutation in the first line, which represents a revolutionary advance for patients," says Elena Elez, principal researcher at the Vall d'Hebron Institute of Oncology in Barcelona and co-investigator of the trial. Furthermore, she recalls that "patients with metastatic colorectal cancer whose tumors host the BRAF V600E mutation u…
A major therapeutic breakthrough in the treatment of metastatic colorectal cancer with a BRAF V600E mutation could radically change the prognosis of this disease. The phase 3 clinical trial BREAKWATER has shown that the combination of the drugs encorafenib and cetuximab, together with chemotherapy, doubles overall survival in patients who had not received previous treatment, compared to standard treatment. The study, presented by Dr. Elena Élez,…
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
